Log in

Relevant bibliographies by topics / IC 5063 / Journal articles

Journal articles on the topic 'IC 5063'

To see the other types of publications on this topic, follow the link: IC 5063.

Author: Grafiati

Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'IC 5063.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mukherjee, Dipanjan, Alexander Y. Wagner, Geoffrey V. Bicknell, Raffaella Morganti, Tom Oosterloo, Nicole Nesvadba, and Ralph S. Sutherland. "The jet–ISM interactions in IC 5063." Monthly Notices of the Royal Astronomical Society 476, no. 1 (January 22, 2018): 80–95. http://dx.doi.org/10.1093/mnras/sty067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Oosterloo, T., A. Tzioumis, J. Reynolds, R. Morganti, Z. Tsvetanov, P. McCulloch, and E. King. "VLBI Observations of the Seyfert Galaxy IC 5063." International Astronomical Union Colloquium 164 (1998): 197–98. http://dx.doi.org/10.1017/s0252921100045188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Simpson, C., M. Ward, and J. Kotilainen. "The obscuration to the nucleus of IC 5063." Monthly Notices of the Royal Astronomical Society 271, no. 1 (November 1, 1994): 250–56. http://dx.doi.org/10.1093/mnras/271.1.250.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Morganti, R., T. Oosterloo, and Z. Tsvetanov. "Gas Outflow in the Seyfert Galaxy IC 5063." International Astronomical Union Colloquium 159 (1997): 310–11. http://dx.doi.org/10.1017/s0252921100040343.

Full text

Abstract:

IC 5063 (PKS 2048–572) is a nearby (z = 0.0110) early-type galaxy hosting a Seyfert 2 nucleus. In broad-band optical images, it shows a complex dust lane, while the ionized gas extends up to ~ 20 kpc and has an unusual X-shaped structure (Danziger et al. 1981, Colina et al. 1990). A faint, very broad emissionline component has been detected (Bergeron et al. 1983, Colina et al. 1991) together with an off-nuclear broad emission-line region (Wagner & Appenzeller 1989). Broad Hα emission was also detected in polarized light (Inglis et al. 1993). Thus, it is likely that this galaxy has a broad-line region which is obscured from our direct view (while the broad-line radiation is scattered into our line of sight by scatterers outside the obscuring regions). The radio luminosity of IC 5063 is nearly two orders of magnitude larger than typical values for nearby Seyferts (Ulvestad & Wilson 1984), making it one of the strongest radio sources found in Seyfert galaxies (1.3 Jy at 1.4 GHz, i.e., 2 × 1023W Hz−1 for H0 = 50 km s−1 Mpc−1). Its H I content is also very high: Danziger et al. (1981) found 1.0 × 1010M⊙, which gives MHI/LB = 0.4, quite anomalous for this type of object.

APA, Harvard, Vancouver, ISO, and other styles

5

Young, S., C. Packham, R. E. Mason, J. T. Radomski, and C. M. Telesco. "Spatially resolved mid-infrared spectroscopy of IC 5063." Monthly Notices of the Royal Astronomical Society 378, no. 3 (June 6, 2007): 888–92. http://dx.doi.org/10.1111/j.1365-2966.2007.11785.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Busko, I. C., and J. E. Steiner. "“On the Broad Hα Component of IC 5063, IC 5135 and NGC 2992”." Symposium - International Astronomical Union 134 (1989): 90–92. http://dx.doi.org/10.1017/s0074180900140446.

Full text

Abstract:

As part of a high resolution (0.55Å) spectroscopic survey of southern Seyfert galaxies, we observed a number of objects in the Hα region. The main goal of this survey is to study the profiles of the narrow lines in Seyfert 1 and Seyfert 2 galaxies. As a by-product, one can search for and analyse weak broad components in Ha that sometimes show up when Seyfert 2 galaxies are observed with high resolution and high signal to noise. Such objects are usually classified as Seyfert 1.8 or 1.9. The search and detailed study of these objects is of great importance for characterizing the weak end of the luminosity function of active galactic nuclei (AGN). The observations were made with a two channel intensified Reticon at the Coude spectrograph of the 1.6m telescope at the Laboratorio Nacional de Astrofisica (CNPq/LNA).

APA, Harvard, Vancouver, ISO, and other styles

7

Tate, Bhagorao Tukaram, Anil Tejerao Kyadampure, Sheo Kumar Pandey, and Madhav Khushalrao Patil. "Multiphase ISM in Nearby Early Type Galaxy IC 5063." International Journal of Astronomy and Astrophysics 08, no. 01 (2018): 79–93. http://dx.doi.org/10.4236/ijaa.2018.81006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kulkarni, V. P., D. Calzetti, L. Bergeron, M. Rieke, D. Axon, C. Skinner, L. Colina, et al. "Unveiling the Hidden Nucleus of IC 5063 with NICMOS." Astrophysical Journal 492, no. 2 (January 10, 1998): L121—L124. http://dx.doi.org/10.1086/311104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Morganti, R., J. Holt, L. Saripalli, T. A. Oosterloo, and C. N. Tadhunter. "IC 5063: AGN driven outflow of warm and cold gas." Astronomy & Astrophysics 476, no. 2 (September 24, 2007): 735–43. http://dx.doi.org/10.1051/0004-6361:20077888.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Busko, I. C., and J. E. Steiner. "Profiles of emission lines in active galactic nuclei - III. Observations of Ha, [N II] and [S II] profiles." Monthly Notices of the Royal Astronomical Society 245, no. 3 (August 1, 1990): 470. http://dx.doi.org/10.1093/mnras/245.3.470.

Full text

Abstract:

Summary High-resolution (FWHM= 28 km s-1) observations of Ha, [N II] λ6548/6583 and [S II] λ6717/6731 emission lines in several southern active galactic nuclei (AGN) are presented. Deblending of the Hα + [N II] profiles was performed using, when available, the [0 III] λ5007 profile shape as a template. Line profile measurements, as well as line intensities, are tabulated. We found to be relatively common among the observed objects the existence of structure in the line cores, pointing to the complexity of the dynamics in the low-velocity emission region. Differences in profile shape and width amongst different lines are also common, indicating that often there is a superposition, on the spectrograph slit, of emission regions with different dynamics and excitation conditions. This superposition is quantified in the case of IC 5063. We found weak, broad Ha emission in IC 5063 and IC 5135. In NGC 2992, we were unable to confirm the presence of a broad Ha component with the same intensity as found by previous authors, which we ascribe to spectral resolution effects.

APA, Harvard, Vancouver, ISO, and other styles

11

Colina, L., W. B. Sparks, and F. Macchetto. "IC 5063 - A merger remnant with a hidden luminous active nucleus." Astrophysical Journal 370 (March 1991): 102. http://dx.doi.org/10.1086/169795.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Maksym, W. Peter, Judy Schmidt, William C. Keel, Giuseppina Fabbiano, Travis C. Fischer, Joss Bland-Hawthorn, Aaron J. Barth, et al. "Crepuscular Rays from the Highly Inclined Active Galactic Nucleus in IC 5063." Astrophysical Journal 902, no. 1 (October 8, 2020): L18. http://dx.doi.org/10.3847/2041-8213/abb9b6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Colina, L., W. B. Sparks, and F. Macchetto. "IC 5063: A Merger Remnant with a Hidden Luminous Active Nucleus: Erratum." Astrophysical Journal 385 (February 1992): 766. http://dx.doi.org/10.1086/170984.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Morganti, R., W. Frieswijk, R. J. B. Oonk, T. Oosterloo, and C. Tadhunter. "Tracing the extreme interplay between radio jets and the ISM in IC 5063." Astronomy & Astrophysics 552 (March 20, 2013): L4. http://dx.doi.org/10.1051/0004-6361/201220734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Oosterloo, T. A., R. Morganti, A. Tzioumis, J. Reynolds, E. King, P. McCulloch, and Z. Tsvetanov. "A Strong Jet-Cloud Interaction in the Seyfert Galaxy IC 5063: VLBI Observations." Astronomical Journal 119, no. 5 (May 2000): 2085–91. http://dx.doi.org/10.1086/301358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Tadhunter, C., R. Morganti, M. Rose, J. B. R. Oonk, and T. Oosterloo. "Jet acceleration of the fast molecular outflows in the Seyfert galaxy IC 5063." Nature 511, no. 7510 (July 2014): 440–43. http://dx.doi.org/10.1038/nature13520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Morganti, R., T. Oosterloo, and Z. Tsvetanov. "A Radio Study of the Seyfert Galaxy IC 5063: Evidence for Fast Gas Outflow." Astronomical Journal 115, no. 3 (March 1998): 915–27. http://dx.doi.org/10.1086/300236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Morganti, Raffaella, Tom Oosterloo, J. B. Raymond Oonk, Wilfred Frieswijk, and Clive Tadhunter. "The fast molecular outflow in the Seyfert galaxy IC 5063 as seen by ALMA." Astronomy & Astrophysics 580 (July 20, 2015): A1. http://dx.doi.org/10.1051/0004-6361/201525860.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Travascio, A., G. Fabbiano, A. Paggi, M. Elvis, W. P. Maksym, R. Morganti, T. Oosterloo, and F. Fiore. "AGN−Host Interaction in IC 5063. I. Large-scale X-Ray Morphology and Spectral Analysis." Astrophysical Journal 921, no. 2 (November 1, 2021): 129. http://dx.doi.org/10.3847/1538-4357/ac18c7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Maksym, W. Peter, Giuseppina Fabbiano, Martin Elvis, Luis C. Ho, Tom Oosterloo, Jingzhe Ma, Andrea Travascio, Travis C. Fischer, and William C. Keel. "A Giant Loop of Ionized Gas Emerging from the Tumultuous Central Region of IC 5063*." Astrophysical Journal 917, no. 2 (August 1, 2021): 85. http://dx.doi.org/10.3847/1538-4357/ac0976.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Inglis, M. D., C. Brindle, J. H. Hough, S. Young, D. J. Axon, J. A. Bailey, and M. J. Ward. "Evidence for an obscured broad-line region in the early-type radio galaxy IC 5063." Monthly Notices of the Royal Astronomical Society 263, no. 4 (August 15, 1993): 895–902. http://dx.doi.org/10.1093/mnras/263.4.895.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Congiu, E., M. Contini, S. Ciroi, V. Cracco, M. Berton, F. Di Mille, M. Frezzato, G. La Mura, and P. Rafanelli. "High-resolution spectroscopy of the extended narrow-line region of IC 5063 and NGC 7212." Monthly Notices of the Royal Astronomical Society 471, no. 1 (June 29, 2017): 562–88. http://dx.doi.org/10.1093/mnras/stx1628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Oosterloo, Tom, J. B. Raymond Oonk, Raffaella Morganti, Françoise Combes, Kalliopi Dasyra, Philippe Salomé, Nektarios Vlahakis, and Clive Tadhunter. "Properties of the molecular gas in the fast outflow in the Seyfert galaxy IC 5063." Astronomy & Astrophysics 608 (December 2017): A38. http://dx.doi.org/10.1051/0004-6361/201731781.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Koyama, Katsuji, Hisamitu Awaki, Kazushi Iwasawa, and Martin J. Ward. "Hard X-ray emission from a narrow-line radio galaxy IC 5063 and obscured active nucleus." Astrophysical Journal 399 (November 1992): L129. http://dx.doi.org/10.1086/186624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lopez-Rodriguez, E., C. Packham, S. Young, M. Elitzur, N. A. Levenson, R. E. Mason, C. Ramos Almeida, A. Alonso-Herrero, T. J. Jones, and E. Perlman. "Estimations of the magnetic field strength in the torus of IC 5063 using near-infrared polarimetry." Monthly Notices of the Royal Astronomical Society 431, no. 3 (March 23, 2013): 2723–36. http://dx.doi.org/10.1093/mnras/stt363.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Dasyra, K. M., F. Combes, T. Oosterloo, J. B. R. Oonk, R. Morganti, P. Salomé, and N. Vlahakis. "ALMA reveals optically thin, highly excited CO gas in the jet-driven winds of the galaxy IC 5063." Astronomy & Astrophysics 595 (November 2016): L7. http://dx.doi.org/10.1051/0004-6361/201629689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hough, J. H., C. Brindle, D. J. Axon, J. Bailey, and W. B. Sparks. "Infrared and optical polarimetry of the radio elliptical IC 5063 (PKS2048 - 57): discovery of a highly polarized non-thermal nucleus." Monthly Notices of the Royal Astronomical Society 224, no. 4 (February 1, 1987): 1013–18. http://dx.doi.org/10.1093/mnras/224.4.1013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tazaki, Fumie, Yoshihiro Ueda, Yuichi Terashima, and Richard F. Mushotzky. "SUZAKUVIEW OF THESWIFT/BAT ACTIVE GALACTIC NUCLEI. IV. NATURE OF TWO NARROW-LINE RADIO GALAXIES (3C 403 AND IC 5063)." Astrophysical Journal 738, no. 1 (August 12, 2011): 70. http://dx.doi.org/10.1088/0004-637x/738/1/70.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Esparza-Arredondo, Donaji, Omaira González-Martín, Deborah Dultzin, Cristina Ramos-Almeida, Jacopo Fritz, Josefa Masegosa, Alice Pasetto, Mariela Martínez-Paredes, Natalia Osorio-Clavijo, and Cesar Victoria-Ceballos. "Physical Parameters of the Torus for the Type 2 Seyfert IC 5063 from Mid-IR and X-Ray Simultaneous Spectral Fitting." Astrophysical Journal 886, no. 2 (November 28, 2019): 125. http://dx.doi.org/10.3847/1538-4357/ab4ced.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Venturi, G., G. Cresci, A. Marconi, M. Mingozzi, E. Nardini, S. Carniani, F. Mannucci, et al. "MAGNUM survey: Compact jets causing large turmoil in galaxies." Astronomy & Astrophysics 648 (April 2021): A17. http://dx.doi.org/10.1051/0004-6361/202039869.

Full text

Abstract:

Context. Outflows accelerated by active galactic nuclei (AGN) are commonly observed in the form of coherent, mildly collimated high-velocity gas directed along the AGN ionisation cones and kinetically powerful (≳1044 − 45 erg s−1) jets. Recent works found that outflows can also be accelerated by low-power (≲1044 erg s−1) jets, and the most recent cosmological simulations indicate that these are the dominant source of feedback on sub-kiloparsec scales, but little is known about their effect on the galaxy host. Aims. We study the relation between radio jets and the distribution and kinematics of the ionised gas in IC 5063, NGC 5643, NGC 1068, and NGC 1386 as part of our survey of nearby Seyfert galaxies called Measuring Active Galactic Nuclei Under MUSE Microscope (MAGNUM). All these objects host a small-scale (≲1 kpc) low-power (≲1044 erg s−1) radio jet that has small inclinations (≲45°) with respect to the galaxy disc. Methods. We employed seeing-limited optical integral field spectroscopic observations from the Multi Unit Spectroscopic Explorer (MUSE) at the Very Large Telescope to obtain flux, kinematic, and excitation maps of the extended ionised gas. We compared these maps with archival radio images and in one case, with Chandra X-ray observations. Results. We detect a strong (up to ≳800–1000 km s−1) and extended (≳1 kpc) emission-line velocity spread perpendicular to the direction of the AGN ionisation cones and jets in all four targets. The gas excitation in this region of line-width enhancement is entirely compatible with shock ionisation. These broad and symmetric line profiles are not associated with a single coherent velocity of the gas. A ‘classical’ outflow component with net blueshifted and redshifted motions is also present, but is directed along the ionisation cones and jets. Conclusions. We interpret the observed phenomenon as due to the action of the jets perturbing the gas in the galaxy disc. These intense and extended velocity spreads perpendicular to AGN jets and cones are indeed currently only observed in galaxies hosting a low-power jet whose inclination is sufficiently low with respect to the galaxy disc to impact on and strongly affect its material. In line with cosmological simulations, our results demonstrate that low-power jets are indeed capable of affecting the host galaxy.

APA, Harvard, Vancouver, ISO, and other styles

31

Tsvetkov, Milcho K., and Katya P. Tsvetkova. "A catalogue of flare stars in the Cygnus region." Symposium - International Astronomical Union 137 (1990): 105–8. http://dx.doi.org/10.1017/s0074180900187546.

Full text

Abstract:

A catalogue of known flare stars in the region of the emission nebulae NGC 7000 - IC 5068-70 and IC 1318 a,b,c in Cygnus is presented. The UBV magnitudes and spectral types, as far as available, for 96 flare stars and their 144 flares were collected. Patrol observations from the Asiago, Byurakan, Konkoly, Rozhen and Tonantzintla observatories, covering a total of 1500 hours effective observing time were used.

APA, Harvard, Vancouver, ISO, and other styles

32

Suárez-López, Leticia, Lourdes Campero, and Elvia De la Vara-Salazar. "Características sociodemográficas y reproductivas asociadas con el aumento de cesáreas en México." Salud Pública de México 55, Supl.2 (March 4, 2013): 225. http://dx.doi.org/10.21149/spm.v55s2.5119.

Full text

Abstract:

Objetivo. Describir la tendencia de la cesárea en México y su asociación con características sociodemográficas y reproductivas. Material y métodos. Con base en Encuestas Nacionales de Salud 2000, 2006 y 2012, se analizó información de cesáreas en mujeres. Se utilizó un modelo de regresión logística multivariado en 2012. Resultados. Se identificó un incremento de 50.3% de la operación cesárea a nivel nacional en el periodo de 2000 a 2012. Las mujeres con mayor posibilidad de tener una cesárea fueron las que se atendieron en el sector privado (RM=2.84, 95%IC:2.15- 3.74). Al asociar la edad y la paridad se observan los riesgos más altos en primíparas de 12 a 19 y de 35 o más años (RM=6.02, 95%IC:1.24-29.26 y RM=5.20, 95%IC:2.41-11.21, respectivamente). Conclusiones. Se proponen algunas recomendaciones encaminadas a revertir el incremento de esta práctica clínica, sobre todo en aquellos casos donde no hay una indicación precisa para su realización.

APA, Harvard, Vancouver, ISO, and other styles

33

Munro, E. G., N. Karnik Lee, M. K. Cheung, K. Osann, A. Husain, N. N. Teng, D. S. Kapp, J. S. Berek, and J. K. Chan. "The role of extensive lymphadenectomy in stage I ovarian cancer." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 5069. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5069.

Full text

Abstract:

5069 Background: To determine if extent of lymphadenectomy affects the survival of women with stage I ovarian cancer. Methods: Demographic and clinico-pathologic information were obtained from the Surveillance, Epidemiology and End Results Program from 1988–2001 and analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Results: Of the 6,686 women diagnosed with stage I ovarian cancer, 4,092 (61.2%) had stage IA, 392 (5.9%) had stage IB, 1,840 (27.5%) had stage IC, and 362 (5.4%) had unspecified stage I disease. The median age was 53 (range: 1–99). 5,625 (84.1%) were White, 388 (5.8%) Black, 488 (7.3%) Asian, and 185 (2.8%) were Other. All patients underwent primary surgery; of which, 3,824 women had no nodes, 1,533 had <10 nodes, and 1,329 had ≥10 nodes resected. Of the patients who underwent a lymphadenectomy, the median number of nodes resected was 9 (range: 1–84). The extent of lymphadenectomy (0, <10, and ≥10 nodes) increased the survival of patients with stage IC disease from 72.8%, 86.7%, to 90.1% (p < 0.0001), but not in those with stage IA (p = 0.07) or stage IB (p = 0.04) disease. In patients with non-clear cell epithelial carcinoma, the extent of lymphadenectomy was associated with improved 5-year disease-specific survivals of 85.6%, 93.3%, and 93.5%, respectively (p < 0.0001). However, the benefit associated with an extensive lymphadenectomy was not evident in clear cell (p = 0.09), sarcoma (p = 0.33), germ cell (p = 0.55), or sex cord stromal tumors of the ovary (p = 0.99). Similarly, patients with grade 3 disease had an improved survival associated with the extent of lymph node resection, 74.4%, 87.5%, to 90.5% (p < 0.0001), but not in those with grade 1 (p = 0.18) or grade 2 (p = 0.27) disease. In multivariate analysis, a more extensive lymphadenectomy remained significant as an independent prognostic factor for improved survival after adjusting for all other independent prognostic factors including age, surgery, histology, stage, and grade. Conclusions: Our findings suggest that the extent of lymphadenectomy was associated with an improvement in the survival of women with stage IC ovarian cancer. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

34

Ruiz-Burneo, Lucía, Jimy A. Merino-Rivera, and Antonio Bernabé-Ortiz. "Diabetes mellitus tipo 2 y características del sueño: un estudio poblacional en Tumbes, Perú." Revista Peruana de Medicina Experimental y Salud Pública 39, no. 1 (March 31, 2022): 55–64. http://dx.doi.org/10.17843/rpmesp.2022.391.10755.

Full text

Abstract:

Objetivo. Determinar si existe asociación entre la presencia de diabetes mellitus tipo 2 (DM2) y la duración, dificultad para dormir, y calidad de sueño, en sujetos de 30 a 69 años en Tumbes. Materiales y métodos. Estudio transversal analítico. Las variables dependientes fueron dificultad para dormir (a veces/casi nunca y frecuentemente), duración del sueño (normal, corto y prolongado) y calidad del sueño (buena y mala). La variable independiente fue la presencia de DM2 evaluada usando la prueba de tolerancia oral a la glucosa (no DM2, con DM2 y sin diagnóstico previo, y con DM2 y diagnóstico previo). Se usó modelos de regresión de Poisson para reportar razones de prevalencia (RP) e intervalos de confianza al 95% (IC 95%). Resultados. Se analizaron 1604 individuos, con una edad media de 48,2 años; 50,3% fueron mujeres; 71 (4,4%) tenían DM2 sin diagnóstico previo y 105 (6,5%) tenían DM2 con diagnóstico previo. Según las características del sueño, 12,0% presentó sueño corto y 8,2% presentó sueño prolongado; 3,7% reportó dificultad para dormir, y 19,5% tuvo mala calidad de sueño. En el modelo multivariable, tener DM2 con diagnóstico previo estuvo asociado con dificultad para dormir (RP = 2,20; IC 95%: 1,13–4,27) y mala calidad de sueño (RP = 1,40; IC 95%: 1,05–1,92) comparado con aquellos sin DM2. Conclusiones. Los individuos con DM2 que tenían diagnóstico previo tuvieron mayor probabilidad de presentar dificultad para dormir y mala calidad de sueño. Nuestros resultados sugieren la necesidad de evaluar en forma periódica las características del sueño en pacientes con DM2.

APA, Harvard, Vancouver, ISO, and other styles

35

Aparicio Ponce, Jorge Renato, and Sandra Teresa Salcedo Hermoza. "Complicaciones obstétricas en multigestas adolescentes. Hospital Nacional Dos de Mayo 2009-2013." Diagnóstico 58, no. 1 (June 13, 2019): 17–22. http://dx.doi.org/10.33734/diagnostico.v58i1.192.

Full text

Abstract:

Objetivo: Determinar las complicaciones obstétricas en multigestas adolescentes. Métodos: Estudio de casos y controles realizado en el Hospital Nacional Dos de Mayo del 2009 al 2013. Se realizó un análisis documental de las historias clínicas de 1,383 gestantes adolescentes. Se utilizó la prueba de chi cuadrado. Para las variables estadísticamente significativas se realizó una regresión logística multinomial. Resultados: Se admitieron 1,383 historias clínicas de gestantes adolescentes; 342 fueron multigestas adolescentes. Se presentaron 334 casos de morbilidad, siendo las más frecuentes la anemia (50,3%), la infección vaginal (18,7%) y la rotura prematura de membranas (11,4%). Solo existió asociación estadísticamente significativa entre ser multigesta adolescente y la hipertensión inducida por el embarazo (p 0,032) (OR=0,54 IC 95% [0,31-0,96]). Conclusiones: La condición de multigesta adolescente protege en el 46% de los casos a padecer de una hipertensión inducida por el embarazo. No existe diferencia de otras morbilidades entre las primigestas y las multigestas adolescentes.

APA, Harvard, Vancouver, ISO, and other styles

36

Aparicio Ponce, Jorge Renato, and Sandra Teresa Salcedo Hermoza. "Complicaciones obstétricas en multigestas adolescentes. Hospital Nacional Dos de Mayo 2009-2013." Diagnóstico 58, no. 1 (December 18, 2019): 17–22. http://dx.doi.org/10.33734/diagnostico.v58i1.29.

Full text

Abstract:

Objetivo: Determinar las complicaciones obstétricas en multigestas adolescentes. Métodos: Estudio de casos y controles realizado en el Hospital Nacional Dos de Mayo del 2009 al 2013. Se realizó un análisis documental de las historias clínicas de 1,383 gestantes adolescentes. Se utilizó la prueba de chi cuadrado. Para las variables estadísticamente significativas se realizó una regresión logística multinomial. Resultados: Se admitieron 1,383 historias clínicas de gestantes adolescentes; 342 fueron multigestas adolescentes. Se presentaron 334 casos de morbilidad, siendo las más frecuentes la anemia (50,3%), la infección vaginal (18,7%) y la rotura prematura de membranas (11,4%). Solo existió asociación estadísticamente significativa entre ser multigesta adolescente y la hipertensión inducida por el embarazo (p 0,032) (OR=0,54 IC 95% [0,31-0,96]). Conclusiones: La condición de multigesta adolescente protege en el 46% de los casos a padecer de una hipertensión inducida por el embarazo. No existe diferencia de otras morbilidades entre las primigestas y las multigestas adolescentes.

APA, Harvard, Vancouver, ISO, and other styles

37

Kocic, Mirjana, Milica Lazovic, Zoran Kojovic, Milorad Mitkovic, Sasa Milenkovic, and Tamara Ciric. "Methods of the physical medicine therapy in prevention of heterotopic ossification after total hip arthroplasty." Vojnosanitetski pregled 63, no. 9 (2006): 807–11. http://dx.doi.org/10.2298/vsp0609807k.

Full text

Abstract:

Background/aim: In the prevention of periarticular heterotopic ossification (HO), a common complication after total hip arthroplasty (THA), nonsteroidal antiinflammatory drugs (NSAID) and irradiation are used. Some theories presume that local hypoxia of the soft tissue causes HO. The aim of this study was to investigate if the early use of pulsed electromagnetic fields (PEMF) could prevent this ossification since it accelerates the circulation and oxigenation of soft tissue. Methods. The study included three groups of the patients with primary THA. The group C consisted of 66 patients/79 hips who had only kinesitherapy in postoperative rehabilitation. The group B consisted of 117 patients/ 131 hips who had PEMF and interferential current (IC) which, on average, started on the 14th day after the surgery combined with the standard kinesitherapy. The group A consisted of 117 patients/131 hips who had PEMF from the third postoperative day and IC from, on average, the 14th postoperative day with the standard kinesitherapy. The classification of HO was done on a standard AP roentgenograms of the hips, taken at least one year after the surgery. Results. The overall HO was seen in 50.63% of the group C patients, in 43.51% of the B group and in 16.67% of the group A. Severe HO (III and IV class according to Brooker) was seen in 26.58% of the group C patients and in 6.10% of the group B, but none in the group A. Conclusion. According to the obtained results an early treatment with PEMF could prevent severe HO and reduce the overall HO.

APA, Harvard, Vancouver, ISO, and other styles

38

Borbón Ramos, Milena Edith, and Franklyn Edwin Prieto Alvarado. "Concordancia y subregistro en la notificación de brotes de enfermedades transmitidas por alimentos en Colombia." Revista de Salud Pública 21, no. 6 (November 1, 2019): 1–6. http://dx.doi.org/10.15446/rsap.v21n6.50268.

Full text

Abstract:

Objetivos Determinar la concordancia y el subregistro entre la notificación de brotes en registros individuales y colectivos de enfermedad transmitida por alimentos, notificados al sistema de vigilancia en salud pública durante 2013.Métodos Análisis retrospectivo a partir de la revisión y depuración de las bases de datos de enfermedades transmitidas por alimentos de registros individuales y colectivos notificados al sistema de vigilancia en salud pública; se determinó la concordancia entre brotes notificados en cada registro por entidad territorial. A través del método captura–recaptura se estableció el subregistro de brotes notificados, estimando la pre- valencia para cada registro. Resultados El 38,4% de los brotes de enfermedades transmitidas por alimentos se noti- ficaron en ambos registros, el 11,3% en colectivo y el 50,3% en individual. Por medio del método de captura y recaptura, se estimaron 1 680 brotes (IC-95%; 1 632-1 730), se determinó que en registro individual se detecta el 77,5% y en colectivo el 43,3% de los brotes estimados, para un subregistro del 12,8% de brotes. Discusión Se estableció una baja concordancia entre ambos registros y un alto subre- gistro en registro colectivo al sistema nacional de vigilancia; lo que dificulta la detección de brotes y oportuna aplicación de medidas de mitigación y control.

APA, Harvard, Vancouver, ISO, and other styles

39

Wimberger, P., R. Kimmig, A. Schulte, M. E. Scheulen, and S. Kasimir-Bauer. "Influence of platinum-based chemotherapy on disseminated tumor cells in patients with primary ovarian cancer." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 5067. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5067.

Full text

Abstract:

5067 Background: Recent studies in patients (pts) with breast cancer have demonstrated the prognostic significance of disseminated tumor cells (DTC) in the bone marrow (BM) which even can survive high-dose chemotherapy. For ovarian cancer, the impact of chemotherapy on DTC is unknown. Here we evaluated whether first-line chemotherapy with carboplatinum and paclitaxel can eliminate DTC in BM and peripheral blood (PB) of pts with primary ovarian cancer (OC, FIGO IC-IIIC). Methods: PB of 28 pts with OC and bilateral BM aspirates of 18/28 pts were assessed for DTC before and after chemotherapy using density gradient centrifugation and an immunocytochemical cytokeratin (CK) assay with the anti-CK antibody A45-B/B3. Results: We identified CK+ cells in 7/28 blood samples (25%) before therapy with a mean number of 2 cells/20 ml (range 1–3). After chemotherapy, CK+ cells were detected in 3/28 blood samples (11%) with a mean number of 9 cells/20 ml (range 1–18). In 5 out of these 7 CK+ patients prior to therapy, no CK+ cells were found after therapy, a no change and a reduction of DTC could be demonstrated in one patient each. CK+ cells were found in 10/18 BM samples (56%) before therapy with a mean number of 2 cells/9x10E6 BM cells (range 1–7) and in 8/18 BM samples (44%) after therapy with a mean number of 10 cells/9x10E6 BM cells (range 2–35). After chemotherapy, no CK+ cells were found in 6 pts, no change in DTC counts was documented in 2 pts and a significant enhancement of DTC was shown in 6 pts, including 4 pts who had no CK+ cells before chemotherapy. Conclusions: DTC are frequently present in the BM and PB of pts with OC and are not always successfully eliminated after platinum-based chemotherapy. It has to be considered, whether these pts might profit from an additive immunotherapy as already shown by the intraperitoneal application of a trifunctional antibody targeting EpCAM, CD3 and accessory cells (Proc Am Assoc Cancer Res 46: 4260, 2005). No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

40

Lasa, Juan, Gustavo Correa, Claudia Fuxman, Laura Garbi, Maria Eugenia Linares, Pablo Lubrano, Astrid Rausch, et al. "Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study." Gastroenterology Research and Practice 2020 (January 17, 2020): 1–9. http://dx.doi.org/10.1155/2020/4060648.

Full text

Abstract:

Background and Aim. Treatment adherence is a frequent problem in inflammatory bowel disease (IBD). No study has assessed adherence in Argentinian patients with IBD. The aim of this study was to determine inadequate adherence to oral and parenteral therapies in patients with IBD from Argentina and to identify factors associated with it. Methods. A multicenter cross-sectional study involving seven referral centers from three cities of Argentina was undertaken. Patients with a diagnosis of ulcerative colitis (UC), Crohn’s disease (CD), or indeterminate colitis (IBDU/IC) were invited to answer an anonymous survey, which included a 5-point Likert scale to evaluate adherence to therapies. Independent variables associated with inadequate adherence were evaluated. Results. Overall, 447 UC/IBDU and 135 CD patients were enrolled. Median age was 37 years (range 21-72); 39.8% were male; median time from diagnosis was 6 years (0.5-35). 91.4% were under treatment with at least one oral medication; 50.3% of patients reported inadequate adherence to oral medications. Patients with UC/IBDU had a lower risk of inadequate adherence when compared to patients with CD (OR 0.57 (0.37-0.87)). 21.8% reported inadequate adherence to biologics; subcutaneous administration was significantly associated with inadequate adherence to biologics (OR 4.8 (1.57-14.66)). Conclusion. Inadequate treatment adherence is common among patients with IBD, and potentially modifiable factors were identified.

APA, Harvard, Vancouver, ISO, and other styles

41

Gallo Villegas, Jaime Alberto, Juan Eugenio Ochoa Múnera, Jon Kepa Balparda Arias, and Dagnovar Aristizábal Ocampo. "Puntos de corte del perímetro de la cintura para identificar sujetos con resistencia a la insulina en una población colombiana." Acta Médica Colombiana 38, no. 3 (September 30, 2013): 118–26. http://dx.doi.org/10.36104/amc.2013.73.

Full text

Abstract:

RESUMEN Introducción: el síndrome metabólico (SM) es una condición clínica que aumenta el riesgo de enfermedad cardiovascular y se relaciona con resistencia a la insulina (RI). Aunque los consensos establecen la necesidad de puntos de corte específicos del perímetro de la cintura (PC) para cada país, con el fin de identificar sujetos con SM, en Colombia no han sido definidos. Objetivo: definir los puntos de corte del PC en hombres y en mujeres que mejor discriminan la presencia de RI, establecer la prevalencia de SM y verificar la relación entre el PC y RI. Materiales y Métodos: en el contexto del estudio Diagnóstico del Riesgo Cardiovascular Global, Medellín 2007-2008, se realizó una evaluación clínica, antropométrica y de laboratorio. Con el índice de resistencia a la insulina HOMA (IR-HOMA) se definió la presencia de RI a partir del percentil 75. Se construyeron curvas de las características operativas del receptor (COR), se obtuvo el área bajo la curva (AUC) para cada sexo y se usó el índice de Youden para establecer el PC que mejor discriminaba la presencia de RI. Resultados: se incluyeron 800 sujetos, de los cuales el 44,8% fueron hombres, con un promedio de edad de 50,3±12,1 e índice de masa corporal (IMC) de 26,1±4,7. Los sujetos con RI tuvieron mayor PC, triglicéridos y presión arterial, además, menor colesterol HDL que aquellos sin RI. Los valores que mejor discriminan la presencia de RI fueron 92 cm en hombres (sensibilidad 82,28%; especificidad 70,14%) y 84 cm en mujeres (sensibilidad 78,15%; especificidad 73,98%) (índice de Youden de 0,52 en ambos sexos). Para los hombres y mujeres el AUC fue 0,828 (IC 95% 0,780-0,876) y 0,815 (IC 95% 0,770-0,859), respectivamente, valor de p< 0,001. Se encontró correlación entre el PC e IR-HOMA (ρ=0,65 en los hombres y ρ=0,62 en las mujeres) y una prevalencia del SM del 44,9%. Conclusión: los valores de PC que mejor discriminaron la presencia de RI son 92 cm para hombres y 84 cm para mujeres. Este criterio podría ser utilizado para identificar sujetos con SM a nivel poblacional.

APA, Harvard, Vancouver, ISO, and other styles

42

Pierqa, J., D. Hajage, T. Bachelot, S. Delaloge, E. Brain, M. Campone, C. Mathiot, L. Mignot, and F. C. Bidard. "5023 POSTER DISCUSSION Cyfra 21-1 Correlation With Circulating Tumour Cells (CTC) Detection and Patient Outcome in Metastatic Breast Cancer: Results of a Substudy of the Prospective IC 2004-06 Trial." European Journal of Cancer 47 (September 2011): S337. http://dx.doi.org/10.1016/s0959-8049(11)71465-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

ARAÚJO, Sâmara N., Yane S. SANTOS, Jamilly A. SANTOS, Amanda S. MORAIS, Izabella V. GOMES, and Daniel T. SILVA. "Estimativa de custo e adesão de prescrições médicas a diretrizes de profilaxia para úlcera de estresse em um hospital universitário no nordeste do Brasil: estudo retrospectivo observacional." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 12, no. 3 (September 14, 2021): 648. http://dx.doi.org/10.30968/rbfhss.2021.123.0648.

Full text

Abstract:

Objetivo: avaliar a adesão das prescrições médicas às principais diretrizes de profilaxia para úlcera de estresse e estimar os gastos despendidos com as prescrições inapropriadas em um hospital universitário na Região Nordeste do Brasil. Métodos: o estudo foi do tipo observacional, transversal, descritivo, retrospectivo com abordagem quantitativa. Analisaram-se prontuários e prescrições médicas de todos os pacientes internados por mais de 24 horas nas unidades de cuidados não intensivos, no período de um mês. Foram excluídos do estudo, pacientes menores de 18 anos, em uso prévio de supressores ácidos para fins de tratamento ou com prontuários preenchidos de forma incompleta. Os dados foram coletados através de instrumento formulado a partir das principais diretrizes para profilaxia para úlcera de estresse, submetidos a analise descritiva, teste Kruskal-Wallis com post-hoc de Dunn, correlação de Pearson e regressão logística. O odds ratio e o intervalo de confiança (95% IC) foram considerados para relatar os resultados do modelo de regressão. Valores de p≤0.05 foram considerados significativos para os demais testes. Resultados: Foram aptos a participar do estudo 421 usuários, sendo a maioria do sexo masculino e na faixa etária entre 30 a 59 anos. Para 212 (50,3%) foi prescrita profilaxia para úlcera de estresse, para 210 (99%) destes não havia indicação nas diretrizes. O custo médio por paciente com profilaxia indevidamente prescrita foi de U$8,6 (DP10,8). Na análise, pelo modelo de regressão logística múltipla, as variáveis associadas à prescrição foram tempo de permanência (OR= 1,047; 1,03-1,07) e ter vínculo profissional Staff (OR= 1,995; 1,30-3,06), ajustadas por idade e sexo. O tempo de permanência e tempo de uso de terapia de supressão ácida foi significantemente maior na clínica ortopédica (p<0,0001). Conclusão: Faz-se necessária medidas de intervenção, incluindo a implementação de protocolos institucionais e educação de prescritores sobre o uso de terapia de supressão ácida durante a hospitalização.

APA, Harvard, Vancouver, ISO, and other styles

44

Martínez-Velarde, Dalia, Renzo Málaga-Chávez, and Antonio Bernabe-Ortiz. "Consumo de bebidas azucaradas, verduras y frutas en sujetos con alteración del metabolismo de la glucosa." Revista Española de Nutrición Humana y Dietética 25, no. 3 (September 30, 2021): 326–36. http://dx.doi.org/10.14306/renhyd.25.3.1258.

Full text

Abstract:

Introducción: Poco se conoce sobre los patrones de dieta de individuos con diabetes mellitus tipo 2 (DM2) en Perú. El objetivo del presente estudio fue determinar si existe asociación entre la alteración del metabolismo de la glucosa y ciertos patrones de dieta (consumo de bebidas azucaradas, verduras y frutas). Material y métodos: Análisis secundario de un estudio poblacional de tipo transversal realizado en Tumbes, en el norte del Perú. Las variables resultado fueron consumo de bebidas azucaradas, consumo de verduras y consumo de frutas, definidas por autoreporte; mientras que la exposición fue la alteración del metabolismo de la glucosa (euglicémico, con DM2 pero sin diagnóstico previo, y con DM2 y diagnóstico previo), basado en la prueba de tolerancia oral a la glucosa. Para evaluar las asociaciones de interés, se crearon modelos de regresión de Poisson con varianza robusta y se reportaron razones de prevalencia (RP) e intervalos de confianza al 95% (IC 95%).Resultados: Un total de 1607 individuos, media de edad de 48,2 (DE: 10,6), y 809 (50,3%) mujeres, fueron incluidos en los análisis. La prevalencia de DM2 fue de 11,0% (IC95%: 9,5%–12,6%), y de ellos, 105 (59,7%) tuvieron diagnóstico previo. Solo 213 (13,3%) consumieron bebidas azucaradas >1 vez/semana, mientras que 409 (25,5%) y 736 (45,8%) consumieron verduras y frutas en forma casi diaria, respectivamente. Aquellos con diagnóstico previo de DM2 tuvieron menor probabilidad de consumir bebidas azucaradas (algunas veces vs. nunca: RP=0,57; IC95%: 0,41–0,78 y >1 vez/semana vs. nunca: RP=0,39; IC95%: 0,18–0,85). Ni el consumo de frutas ni el de verduras fue mayor en aquellos con o sin diagnóstico previo de DM2.Conclusiones: Comparados con los euglicémicos, los individuos con diagnóstico previo de DM2 tuvieron un menor consumo de bebidas azucaradas, pero dicha asociación no estuvo presente en aquellos con DM2 sin diagnóstico previo. El consumo de frutas y verduras no fue diferente entre las categorías de alteración del metabolismo de la glucosa estudiadas.

APA, Harvard, Vancouver, ISO, and other styles

45

Ansari, Shaheryar F., Colin Terry, and Aaron A. Cohen-Gadol. "Surgery for vestibular schwannomas: a systematic review of complications by approach." Neurosurgical Focus 33, no. 3 (September 2012): E14. http://dx.doi.org/10.3171/2012.6.focus12163.

Full text

Abstract:

Object Various studies report outcomes of vestibular schwannoma (VS) surgery, but few studies have compared outcomes across the various approaches. The authors conducted a systematic review of the available data on VS surgery, comparing the different approaches and their associated complications. Methods MEDLINE searches were conducted to collect studies that reported information on patients undergoing VS surgery. The authors set inclusion criteria for such studies, including the availability of follow-up data for at least 3 months, inclusion of preoperative and postoperative audiometric data, intraoperative monitoring, and reporting of results using established and standardized metrics. Data were collected on hearing loss, facial nerve dysfunction, persistent postoperative headache, CSF leak, operative mortality, residual tumor, tumor recurrence, cranial nerve (CN) dysfunction involving nerves other than CN VII or VIII, and other neurological complications. The authors reviewed data from 35 studies pertaining to 5064 patients who had undergone VS surgery. Results The analyses for hearing loss and facial nerve dysfunction were stratified into the following tumor categories: intracanalicular (IC), size (extrameatal diameter) < 1.5 cm, size 1.5–3.0 cm, and size > 3.0 cm. The middle cranial fossa approach was found to be superior to the retrosigmoid approach for hearing preservation in patients with tumors < 1.5 cm (hearing loss in 43.6% vs 64.3%, p < 0.001). All other size categories showed no significant difference between middle cranial fossa and retrosigmoid approaches with respect to hearing loss. The retrosigmoid approach was associated with significantly less facial nerve dysfunction in patients with IC tumors than the middle cranial fossa method was; however, neither differed significantly from the translabyrinthine corridor (4%, 16.7%, 0%, respectively, p < 0.001). The middle cranial fossa approach differed significantly from the translabyrinthine approach for patients with tumors < 1.5 cm, whereas neither differed from the retrosigmoid approach (3.3%, 11.5%, and 7.2%, respectively, p = 0.001). The retrosigmoid approach involved less facial nerve dysfunction than the middle cranial fossa or translabyrinthine approaches for tumors 1.5–3.0 cm (6.1%, 17.3%, and 15.8%, respectively; p < 0.001). The retrosigmoid approach was also superior to the translabyrinthine approach for tumors > 3.0 cm (30.2% vs 42.5%, respectively, p < 0.001). Postoperative headache was significantly more likely after the retrosigmoid approach than after the translabyrinthine approach, but neither differed significantly from the middle cranial fossa approach (17.3%, 0%, and 8%, respectively; p < 0.001). The incidence of CSF leak was significantly greater after the retrosigmoid approach than after either the middle cranial fossa or translabyrinthine approaches (10.3%, 5.3%, 7.1%; p = 0.001). The incidences of residual tumor, mortality, major non-CN complications, residual tumor, tumor recurrence, and dysfunction of other cranial nerves were not significantly different across the approaches. Conclusions The middle cranial fossa approach seems safest for hearing preservation in patients with smaller tumors. Based on the data, the retrosigmoid approach seems to be the most versatile corridor for facial nerve preservation for most tumor sizes, but it is associated with a higher risk of postoperative pain and CSF fistula. The translabyrinthine approach is associated with complete hearing loss but may be useful for patients with large tumors and poor preoperative hearing.

APA, Harvard, Vancouver, ISO, and other styles

46

Stary, Jan, Martin Zimmermann, Myriam Campbell, Luis Castillo, Eduardo Dibar, Svetlana Donska, Alejandro Gonzalez, et al. "Results of the Randomized I-BFM-SG Trial „Acute Lymphoblastic Leukemia Intercontinental-BFM 2002“ in 5060 Children Diagnosed in 15 Countries on 3 Continents." Blood 118, no. 21 (November 18, 2011): 872. http://dx.doi.org/10.1182/blood.v118.21.872.872.

Full text

Abstract:

Abstract Abstract 872 Introduction: ALL IC-BFM 2002 is one of the most successful projects developed by the I-BFM-SG, which is one of the world largest societies involving national leukemia groups. The trial evaluated in a randomized manner the impact on outcome of intensified late reinduction in the context of a newly developed risk stratification. The main goal of the trial was improvement of outcome of children with ALL in each of the 3 risk groups (RG). Patients & methods: From Nov 2002-Nov 2007, 5060 eligible pts aged 0–18 yrs with newly diagnosed ALL from Argentina (1270), Chile (558), Croatia (122), Cuba (151), Czech Republic (291), Hong Kong (155), Hungary (259), Israel (292), Poland (908), Serbia (266), Slovakia (137), Slovenia (36), Ukraine (421), Uruguay (96), and Moscow (98) were enrolled in the trial (http:clinicaltrials.gov “NCT00764907”). Stratification into 3 RGs was based on early treatment response (evaluated in PB on day 8 and in BM on days 15 and 33), age, initial WBC, and presence/absence of BCR/ABL or MLL/AF4. Standard Risk (SR) criteria were: < 1,000 blasts/μL in PB day 8 after 7 days of oral prednisone with 1 intrathecal methotrexate (IT-MTX) and age ≥ 1 yr and < 6 yr and initial WBC < 20,000/μL and M1 or M2 marrow on day 15 and M1 marrow on day 33 (all criteria must be fulfilled). Intermediate Risk (IR) criteria were: < 1,000 blasts/μL in PB day 8 and age < 1 yr or ≥ 6 yr and/or WBC ≥ 20,000/μL and M1 or M2 marrow on day 15 and M1 marrow on day 33 (or SR criteria but M3 marrow on day 15 and M1 marrow on day 33). High Risk (HR) criteria were: IR and M3 marrow on day 15, PB on day 8 ≥ 1,000 blasts/μL, M2 or M3 marrow on day 33, translocation t(9;22) [BCR/ABL] or t(4;11) [MLL/AF4] (at least one criterion must be fulfilled). The majority of infants < 1 yr were treated in studies Interfant 99 and Interfant 06. Treatment consisted of protocol I‘/I, SR/IR consolidation with 6-MP and MD MTX 2g/m2 × 4 (with additional IT-MTX in maintenance) for BCP-ALL, 6-MP and HD MTX 5g/m2 × 4 for T-ALL, HR consolidation with 3 HR polychemotherapy blocks. A randomized question was asked in late intensification: SR: would 2 shorter elements (protocol III × 2) be more effective than 1 longer (protocol II × 1) even though the cumulative dose of most drugs is not increased? IR: could the risk of failure be reduced by a third reintensification element (protocol III × 3)? HR: could the use of 3 reintensification elements (protocol III × 3) achieve the same or better results than the HR approach applied in BFM (3 HR blocks + protocol II × 1) or AIEOP (protocol II × 2)? Chemotherapy was concluded by maintenance therapy (6-MP/MTX), making up a total of 2 yrs overall treatment. Prophylactic CNS radiotherapy 12 Gy was applied in T-ALL and HR pts. Results: With median follow-up 4.9 yr, the 5-yr EFS was 74 ± 1% and 5-yr OS 82 ± 1% for the whole group of 5060 pts. The CR rate was 97%, 255 (5%) children died in remission. The 5-yr EFS/OS was 81 ± 1%/90 ± 1% in 1564 SR pts (30.9% of all pts), 75 ± 1%/83 ± 1% in 2650 IR pts (52.4%) and 55 ± 2%/62 ± 2% in 846 HR pts (16.7%). Randomization rate was 79% of those patients who survived for at least 20 weeks (planned timepoint of randomization). None of the experimental arms achieved significantly better EFS compared to standard treatment. CI of relapses at 5 yr was 18 ± 1% overall, CI for isolated BM relapse was 12 ± 1%, isolated and combined CNS relapse 4 ± 0.3%, isolated and combined testicular relapse 2 ± 0.2%. Secondary malignancy was diagnosed so far in 26 patients (5-yr CI 0.6 ± 0.1%). Significantly better EFS was achieved in BCP-ALL(75 ± 1%) in comparison with T-ALL (69 ± 1%), girls vs. boys (76 ± 1% vs 72 ± 1%), children aged < 10 yr vs ≥ 10 yr (77 ± 1% vs 65 ± 1%), M1/M2 BM D15 vs. M3(76 ± 1% vs 50 ± 3%). 140 pts with Ph+ALL achieved a EFS of 47 ± 4% Allogeneic HSCT in CR1 was done in 139 pts with 5 -yr DFS of 64 ± 4%. Conclusions: Although the experimental arm was no better than the traditional one across individual RGs, the majority of participating countries, many of them were new-comers to this intensive therapy, improved their treatment results against previous national studies. The trial confirmed the validity and feasibility of a simple risk stratification of ALL applied in a complex and heterogeneous multinational environment. Despite the great differences between individual countries, the trial set a firm stage for willing national leukemia groups to run collaborative clinical trials in ALL under the umbrella of I-BFM-SG. Supported by MSM0021620813 and MZ0FNM2005. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

47

Mateos, Maria-Victoria, Norma C. Gutierrez, María-Luisa Martín, Joaquín Martínez-López, Miguel T. Hernandez, Rafael Martinez, Laura Rosiñol, et al. "Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)." Blood 126, no. 23 (December 3, 2015): 4243. http://dx.doi.org/10.1182/blood.v126.23.4243.4243.

Full text

Abstract:

Abstract Background: Novel insights into the biology of myeloma cells have led to the identification of relevant prognosis factors. CA has become one of the most important prognostic factors, and the presence of t(4;14), t(14;16) or del(17p) are associated with poor prognosis. Although there are some reports indicating that 1q gains may be considered as a poor-risk feature, the information is not uniform. Furthermore, there are important controversies about whether or not novel agents-based combinations are able to overcome the poor prognosis of CA. Bortezomib-based combinations have shown to improve the outcome of patients with high-risk CA but they do not completely overcome their adverse prognosis. Here we report a preplanned analysis, in a series of elderly newly diagnosed myeloma patients included in the Spanish GEM2010 trial and receiving VMP and Rd, in a sequential or alternating approach, in order to evaluate the influence of CA by FISH on the response rate and outcome. Patients and methods: 242 pts were randomized to receive a sequential scheme consisting on 9 cycles of VMP followed by 9 cycles of Rd or the same regimens in an alternating approach (one cycle of VMP alternating with one Rd, up to 18 cycles. VMP included the iv administration of weekly bortezomib (except in the first cycle that was given twice weekly) at 1.3 mg/m2 in combination with oral melphalan 9 mg/m2 and prednisone 60 mg/m2 once daily on days 1-4. Rd treatment consisted on lenalidomide 25 mg daily on days 1-21 plus dexamethasone 40 mg weekly. FISH analysis for t(4;14), t(14;16), del(17p) and 1q gains was performed at diagnosis according to standard procedures using purified plasma cells. Results: In 174 out of the 233 patients evaluable for efficacy and safety, FISH analysis at diagnosis were available and two groups were identified: high-risk group (n= 32 patients with t(4;14) and/or t(14;16) and/or del(17p)) and standard-risk group (n=142 patients without high-risk CA). There weren't differences in the rates of CA according to the treatment arm. Response Rates (RR) were no different in the high-risk vs standard-risk groups, both in the sequential (74% vs 79% RR and 42% vs 39% CR) and alternating arms (69% vs 86% RR and 39% vs 38% CR). After a median follow-up of 37 months, high-risk patients showed shorter PFS as compared to standard risk in the alternating arm (24 versus 36 months, p=0.01, HR 2.2, 95% IC 1.1-4.2) and this also translated into a significantly shorter 4-years OS (27% vs 72%, p=0.006, HR 3.3, 95% IC 1.4-7.7). However, in the sequential arm, high-risk and standard-risk patients showed similar PFS (32 months vs 30 months) and 4-years OS (64% vs 60%). This effect was observed only in the sequential arm applied to either t(4;14) or del(17p). As far as 1q gains is concerned, 151 patients had 1q information and 76 of them had 1q gains (50.3%), defined as the presence of more than 3 copies in at least 10% of plasma cells. The rate of 1q gains was well balanced in both sequential and alternating arms. The ORR was similar in patients with or without 1q gains (83% vs 80%) as well as the CR rate (45% vs 31%), and no differences were observed between sequential and alternating arms. Patients with or without 1q gains had a similar PFS (33 months vs 30 months) and 4-years OS (58% vs 65%) in the whole series and no differences were observed in the sequential and alternating arms. This effect has been observed in patients with 1q gains as isolated CA and the outcome was slightly but not significantly worse when 1q gains were present plus either t(4;14) and/or del17p. Conclusions: The total therapy approach including VMP and Rd administered in a sequential approach is able to overcome the poor prognosis of the presence of high-risk CA in elderly patients with newly diagnosed MM. The presence of 1q gains has no impact in the PFS and OS of elderly patients treated with VMP and Rd. Disclosures Mateos: Celgene: Consultancy, Honoraria; Onyx: Consultancy; Janssen-Cilag: Consultancy, Honoraria; Takeda: Consultancy. Gironella:Celgene Corporation: Consultancy, Honoraria. Paiva:BD Bioscience: Consultancy; Binding Site: Consultancy; Sanofi: Consultancy; EngMab AG: Research Funding; Onyx: Consultancy; Millenium: Consultancy; Janssen: Consultancy; Celgene: Consultancy. Puig:Janssen: Consultancy; The Binding Site: Consultancy. San Miguel:Millennium: Honoraria; Janssen-Cilag: Honoraria; Novartis: Honoraria; Celgene: Honoraria; Bristol-Myers Squibb: Honoraria; Onyx: Honoraria; Sanofi-Aventis: Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

48

Zeidan, Amer M., Michael W. Schuster, Jürgen Krauter, Johan A. Maertens, Emmanuel Gyan, Magalie Joris, Tobias F. Menne, et al. "Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia." Blood 134, Supplement_1 (November 13, 2019): 3916. http://dx.doi.org/10.1182/blood-2019-124034.

Full text

Abstract:

Introduction: Attempts to improve on the 20% complete remission (CR) rate and 10.4 month median overall survival (OS) in the frontline treatment (1L) of older unfit patients (pts) with acute myeloid leukemia (AML) using azacitidine (AZA) combination therapy have been met with cytopenic complications that may result in cycle (Cyc) 2 dose delays as frequently as 33% of the time. Glasdegib in combination with low-dose cytarabine (LDAC) showed superior overall survival vs LDAC alone in the BRIGHT AML 1003 trial that included pts with newly diagnosed AML who were ineligible for intensive chemotherapy (IC). The combination did not appear to increase cytopenias, bleeding, or infection. We analyzed the safety profile of glasdegib in combination with AZA or LDAC in 1L AML, focusing on cytopenias, infections, and dose delays. Methods: BRIGHT MDS & AML 1012 (NCT02367456) is an ongoing single-arm study in which untreated pts with myelodysplastic syndromes (MDS) or AML who were ineligible for IC received glasdegib (100 mg once daily [QD]) + AZA (75 mg/m2/day) on Days 1-7 every 28 days until disease progression, unacceptable toxicity, death, or pt refusal. Efficacy outcomes are reported as of Jun 17, 2019; all others as of Apr 19, 2019. BRIGHT AML 1003 (NCT01546038) is a completed study in which untreated pts with MDS or AML who were ineligible for IC were randomized to receive glasdegib (100 mg QD) + LDAC (20 mg twice daily on Days 1-10 every 28 days) or LDAC alone. Outcomes reported as of Oct 11, 2018. To minimize bias due to imbalances in survival between the 1003 study arms, safety outcomes within the first 90 days for the AML cohorts of each study are presented here. Results: Thirty pts with AML received treatment with glasdegib + AZA (Table 1). Median treatment duration was 5 Cyc (range, 1-11); median follow-up time was 7.8 months (95% CI, 5.9-9.6). CR was achieved by 6 pts (20.0%) receiving glasdegib + AZA. Two additional pts achieved CR with incomplete hematologic recovery (CRi) and discontinued treatment to prepare for transplant. Six-month survival probability was 70.0% (95% CI, 50.3-83.1), with 19 pts still in survival follow-up. Pts (N=116) were assigned to treatment with glasdegib + LDAC (n=78) or LDAC alone (n=38 [Table 1]); median treatment duration (range) was 3 Cyc (1-44) for glasdegib + LDAC and 2 Cyc (1-9) for LDAC alone; median follow-up time (95% CI) was 43.4 (39.7-49.1) and 42.0 (CI not evaluable) months, respectively. As previously reported, glasdegib + LDAC significantly improved OS vs LDAC alone (hazard ratio, 0.495 [95% CI, 0.325-0.752]; P=0.0004). The incidence of select treatment-emergent adverse events (TEAEs) and serious TEAEs associated with cytopenias, bleeding, and infection did not appear worse with glasdegib + AZA or glasdegib + LDAC than with LDAC alone, with some AEs even occurring less frequently (Table 1). Dose delays due to AEs were required in Cyc 2 by 8.7% (n=2/23, glasdegib + AZA), 6.7% (n=4/60, glasdegib + LDAC), and 4.2% (n=1/24, LDAC alone) of pts. Recovery of absolute neutrophil count, hemoglobin, and platelets at 2 cell-count thresholds was seen as early as Cyc 1 in approximately half of the evaluable pts (Table 2). Gastrointestinal toxicities, including nausea and vomiting, were frequent in pts receiving glasdegib + AZA (60.0 and 40.0%, respectively) and glasdegib + LDAC (29.3 and 20.0%, respectively). Glasdegib treatment was associated with AEs thought to be linked to inhibition of the Hedgehog pathway in normal tissue (muscle spasms, dysgeusia, alopecia [Table 1]). Conclusions: The addition of glasdegib to AZA does not appear to increase hematologic toxicities or cytopenic complications substantially, in contrast to the increased toxicity typically observed with combinational therapy. In the context of different baseline characteristics of the populations studied with AZA alone in 1L AML (Dombret, et al. Blood 2016), glasdegib + AZA did not substantially increase AEs related to cytopenias like infections, especially given the low rates of Cyc 2 delays due to AEs. These results are consistent with the lack of substantially increased toxicities with glasdegib + LDAC vs LDAC alone. In light of the survival benefit observed with glasdegib + LDAC vs LDAC alone, the addition of glasdegib to AZA may improve clinical outcomes without substantially increasing toxicities. A randomized phase 3 trial looking at the addition of glasdegib to AZA (vs AZA alone) in 1L AML (NCT03416179) is ongoing. Disclosures Zeidan: Astellas: Honoraria; Abbvie: Consultancy, Honoraria, Research Funding; Daiichi Sankyo: Honoraria; Cardinal Health: Honoraria; Seattle Genetics: Honoraria; BeyondSpring: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Otsuka: Consultancy, Honoraria, Research Funding; Medimmune/AstraZeneca: Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Trovagene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; ADC Therapeutics: Research Funding; Jazz: Honoraria; Ariad: Honoraria; Agios: Honoraria; Novartis: Honoraria; Acceleron Pharma: Consultancy, Honoraria, Research Funding; Celgene Corporation: Consultancy, Honoraria, Research Funding. Schuster:Incyte: Research Funding; Karyopharm Therapeutics: Research Funding; Morphosys: Research Funding; Nordic Nanovector: Research Funding; Pharmacyclics: Research Funding, Speakers Bureau; Rafael: Research Funding; F2G Ltd.: Research Funding; AbbVie: Speakers Bureau; Amgen: Speakers Bureau; Astellas: Speakers Bureau; Celgene: Speakers Bureau; Genentech: Speakers Bureau; Janssen: Speakers Bureau; Novartis: Speakers Bureau; Seattle Genetics: Speakers Bureau; Takeda: Speakers Bureau; Verastem: Speakers Bureau; Actinium: Research Funding. Krauter:Pfizer: Honoraria. Maertens:Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support; Cidara: Other: Personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support. Gyan:Pfizer: Honoraria. Menne:Kite/Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding, Speakers Bureau. Vyas:Astellas: Speakers Bureau; Abbvie: Speakers Bureau; Novartis: Research Funding, Speakers Bureau; Forty Seven, Inc.: Research Funding; Celgene: Research Funding, Speakers Bureau; Pfizer: Speakers Bureau; Daiichi Sankyo: Speakers Bureau. Ma:Pfizer: Employment, Equity Ownership. O'Connell:Pfizer: Employment, Equity Ownership. Zeremski:Pfizer: Employment, Equity Ownership. Kudla:Pfizer: Employment, Equity Ownership. Chan:Pfizer Inc: Employment, Equity Ownership. Sekeres:Millenium: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. OffLabel Disclosure: Glasdegib is approved in the US in combination with low-dose cytarabine for treatment of newly diagnosed AML in patients not suitable for intensive chemotherapy due to comorbidities or age (75 years or older). Here we report data from a phase 1b trial where glasdegib was combined with azacitidine in patients with AML similarly ineligible for intensive chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

49

Montesinos, Pau, Christian Recher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, et al. "AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation." Blood 138, Supplement 1 (November 5, 2021): 697. http://dx.doi.org/10.1182/blood-2021-147805.

Full text

Abstract:

Abstract Background: Somatic mutations in isocitrate dehydrogenase 1 (IDH1) occur in 6-10% of patients with acute myeloid leukemia (AML). Ivosidenib - an oral, potent inhibitor of the mutant IDH1 (mIDH1) enzyme - is FDA-approved for adults with relapsed/refractory m IDH1 AML and adults with newly diagnosed m IDH1 AML who are ≥ 75 years or have comorbidities that preclude use of intensive induction chemotherapy (IC). Data from a phase 1b study of 23 patients with newly diagnosed m IDH1 AML showed a favorable safety profile and encouraging clinical activity of ivosidenib + azacitidine (IVO+AZA; NCT02677922). Methods: In this global, double-blind, randomized, placebo-controlled, phase 3 study, patients were randomized 1:1 to IVO 500 mg once daily + AZA 75 mg/m 2 subcutaneously or intravenously for 7 days in 28-day cycles, or placebo + AZA (PBO+AZA), and stratified by region and de novo vs secondary AML. Key eligibility: untreated AML (WHO criteria), centrally confirmed m IDH1 status, not eligible for IC, ECOG 0-2. Primary endpoint: event-free survival (EFS; time from randomization until treatment failure, i.e. failure to achieve complete remission [CR] by week 24, relapse from remission, or death from any cause). Key secondary endpoints: CR rate, overall survival (OS), CR + CR with partial hematologic recovery (CRh) rate, and objective response rate (ORR). Results: From 19-Mar-2018 to 18-Mar-2021, 146 patients were randomized: 72 to IVO+AZA (median [interquartile range] age, 76.0 [70.5-79.5] years) and 74 to PBO+AZA (median [interquartile range] age, 75.5 [70.0-80.0] years). Fifty-four (75.0%) patients had de novo AML vs 18 (25.0%) with secondary AML in the IVO+AZA arm. Sixteen (22.2%) patients receiving IVO+AZA had poor-risk genetics per ELN guidelines vs 20 (27.0%) patients receiving PBO+AZA. Thirty-nine (26.7%) patients remain on treatment (27/72 patients in the IVO+AZA arm vs 12/74 patients in the PBO+AZA arm). EFS was statistically significant (HR = 0.33 [95% CI 0.16, 0.69]; P = 0.0011) in favor of the IVO+AZA arm. Median OS with IVO+AZA was 24.0 months vs 7.9 months with PBO+AZA (HR = 0.44 [95% CI 0.27, 0.73]; P = 0.0005). CR rate with IVO+AZA was 47.2% (34/72 patients; 95% CI 35.3%, 59.3%) vs 14.9% (11/74 patients; 95% CI 7.7%, 25.0%) with PBO+AZA (P < 0.0001). Median time to CR was 4.3 months with IVO+AZA vs 3.8 months with PBO+AZA. CR+CRh rate with IVO+AZA was 52.8% (38/72 patients; 95% CI 40.7%, 64.7%) vs 17.6% (13/74 patients; 95% CI 9.7%, 28.2%) with PBO+AZA (P < 0.0001). The CR rate by 24 weeks for IVO+AZA vs PBO+AZA was 37.5% and 10.8%, respectively. ORR with IVO+AZA was 62.5% (45/72 patients; 95% CI 50.3%, 73.6%) vs 18.9% (14/74 patients; 95% CI 10.7%, 29.7%) with PBO+AZA (P < 0.0001). All reported P-values are 1-sided. Common all-grade adverse events (AEs) occurring in > 20% of patients receiving IVO+AZA vs PBO+AZA were nausea (42.3% vs 38.4%), vomiting (40.8% vs 26.0%), diarrhea (35.2% vs 35.6%), pyrexia (33.8% vs 39.7%), anemia (31.0% vs 28.8%), febrile neutropenia (28.2% vs 34.2%), thrombocytopenia (28.2% vs 20.5%), constipation (26.8% vs 52.1%), and pneumonia (23.9% vs 31.5%). Sixty-six (93.0%) patients receiving IVO+AZA vs 69 (94.5%) patients receiving PBO+AZA experienced a grade ≥ 3 AE. Common grade ≥ 3 AEs occurring in > 20% of patients receiving IVO+AZA vs PBO+AZA included febrile neutropenia (28.2% vs 34.2%), anemia (25.4% vs 26.0%), thrombocytopenia (23.9% vs 20.5%), and pneumonia (22.5% vs 28.8%). Frequency of all-grade differentiation syndrome (DS) as assessed by investigators was 14.1% with IVO+AZA vs 8.2% with PBO+AZA, and that of grade ≥ 3 DS was 4.2% with IVO+AZA vs 4.1% with PBO+AZA. Based on the recommendation of the Independent Data Monitoring Committee, further enrollment into the study was prematurely discontinued due to evidence of benefit. Conclusions: IVO+AZA significantly improved EFS, OS, and clinical response (CR, CR+CRh, ORR) compared with PBO+AZA in patients with IC-ineligible, newly diagnosed m IDH1 AML. The safety profile of IVO+AZA was favorable and consistent with previous studies. These data demonstrate the clinical benefit of IVO+AZA in this difficult-to-treat AML population. Disclosures Montesinos: Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Teva: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Stemline/Menarini: Consultancy; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Forma Therapeutics: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Glycomimetics: Consultancy; Tolero Pharmaceutical: Consultancy; Agios: Consultancy; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astellas Pharma, Inc.: Consultancy, Honoraria, Other: Advisory board, Research Funding, Speakers Bureau. Recher: Incyte: Honoraria; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria; Macrogenics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; MaatPharma: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Wang: AbbVie: Consultancy; Astellas Pharma, Inc.: Research Funding. Heuser: Tolremo: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer Pharma AG: Research Funding; Astellas: Research Funding; BergenBio: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Calado: AA&MDS International Foundation: Research Funding; Agios: Membership on an entity's Board of Directors or advisory committees; Team Telomere, Inc.: Membership on an entity's Board of Directors or advisory committees; Novartis Brasil: Honoraria; Instituto Butantan: Consultancy; Alexion Brasil: Consultancy. Schuh: Kite/Gilead: Research Funding; GlycoMimetics: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Membership on an entity's Board of Directors or advisory committees; Teva: Honoraria, Membership on an entity's Board of Directors or advisory committees. Daigle: Agios: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Servier: Current Employment. Hui: Servier: Current Employment; Agios: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Boehringer Ingelheim: Ended employment in the past 24 months. Zhang: Servier: Current Employment; Agios: Current equity holder in publicly-traded company, Ended employment in the past 24 months. Pandya: Agios: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Servier: Current Employment. Gianolio: Servier: Current Employment; Agios: Current equity holder in publicly-traded company, Ended employment in the past 24 months. de Botton: Pierre Fabre: Other; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Honoraria; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Syros: Honoraria, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Forma Therapeutics: Honoraria, Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees. Döhner: Oxford Biomedicals: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; GEMoaB: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Pfizer: Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Berlin-Chemie: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Jazz: Consultancy, Honoraria, Research Funding; Helsinn: Consultancy, Honoraria; Astex: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Agios: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Ulm University Hospital: Current Employment. OffLabel Disclosure: 1) Ivosidenib (AG-120) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test in: i) Adult patients with newly diagnosed AML who are 75 years of age or older or who have comorbidities that preclude use of intensive induction chemotherapy ii) Adult patients with relapsed or refractory AML. 2) It is being evaluated in a clinical trial in combination with azacitidine in adults 18 years of age or older with previously untreated acute myeloid leukemia with an IDH1 mutation.

APA, Harvard, Vancouver, ISO, and other styles

50

Holden, Luke R., Clive N. Tadhunter, Raffaella Morganti, and Tom Oosterloo. "Precise physical conditions for the warm gas outflows in the nearby active galaxy IC 5063." Monthly Notices of the Royal Astronomical Society, January 14, 2023. http://dx.doi.org/10.1093/mnras/stad123.

Full text

Abstract:

Abstract AGN-driven outflows are now routinely used in models of galaxy evolution as a feedback mechanism, however many of their properties remain highly uncertain. Perhaps the greatest source of uncertainty is the electron density of the outflowing gas, which directly affects derived kinetic powers and mass outflow rates. Here we present spatially-resolved, wide spectral-coverage Xshooter observations of the nearby active galaxy IC 5063 (z = 0.001131), which shows clear signatures of outflows being driven by shocks induced by a radio jet interacting with the ISM. For the first time, we use the higher critical-density transauroral [SII] and [OII] lines to derive electron densities in spatially-resolved observations of an active galaxy, and present evidence that the lines are emitted in the same spatial regions as other key diagnostic lines. In addition, we find that the post-shock gas is denser than the pre-shock gas, possibly due to shock compression effects. We derive kinetic powers for the warm ionised outflow phase and find them to be below those required by galaxy evolution models; however, other studies of different gas phases in IC 5063 allow us to place our results in a wider context in which the cooler gas phases constitute most of the outflowing mass. We investigate the dominant ionisation and excitation mechanisms and find that the warm ionised outflow phase is dominated by AGN-photoionisation, while the warm molecular phase has composite AGN-shock excitation. Overall, our results highlight the importance of robust outflow diagnostics and reinforce the utility of the transauroral lines for future studies of outflows in active galaxies.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!